Investor Relations

Latest News

View All News

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

Read Press Release

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

Read Press Release
employees discussing with whiteboard

Recent Event

BIO-Europe 2024

Company Information

FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy.

View Executive Team
View Board of Directors

Latest Financial Results

Q3 2024

Quarter Ended Sep 30, 2024

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

IR Contacts

Company

FibroBiologics, Inc.
455 E. Medical Center Blvd.
Suite 300
Houston, TX 77598
T: 281-671-5150
info@fibrobiologics.com

Investor Relations

Russo Partners
Nic Johnson
T: 212-845-4242
fibrobiologicsIR@russopr.com

Transfer Agent

VStock Transfer LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436